Total
0
Shares
Alcidion (ASX:ALC) - MD, Kate Quirke
MD, Kate Quirke
Source: Alcidion
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Healthcare tech stock Alcidion (ALC) is expecting to officially end FY21 in a strong position following a year of growth
  • Based on current unaudited results, Alcidion is expecting to report revenue for the full year of between $25.6 and $25.9 million, a 38-39 per cent increase from last year and a record full-year result for the company
  • Alcidion continued to build on the momentum through the second half, delivering revenue of $14.5 – $14.8 million
  • Alcidion begins FY22 with $15.1 million of contracted revenue, 18 per cent higher than at the same time last year
  • Alcidion is up 7.04 per cent at 38 cents per share at 10:36 am AEST

Alcidion Group (ALC) has ended FY21 in a strong position following a year of growth for the company.

Based on current unaudited results, Alcidion is expecting to report revenue for the full year of between $25.6 and $25.9 million, including 2.5 months of ExtraMed revenue. This is a 38-39 per cent increase from last year and a record full-year result for the company.

Following a strong first half of the year, Alcidion continued to build on the momentum through the second half, delivering revenue of $14.5 – $14.8 million, a 39- 42 per cent increase from this time last year.

During the fourth quarter, the company signed new contracts and renewals with a total contract value of $7.3 million. However the majority of the balance will be recognised in FY22.

Cash balance at the end of the period was recorded at $25 million.

Alcidion begins FY22 with $15.1 million of contracted revenue, 18 per cent higher than at the same time last year.

In April, the company signed a contract with The Australian Government’s Department of Defence. The contract aims to deliver a system that records, stores and analyses health information for the defence force to improve occupational care.

Commenting on the results Managing Director Kate Quirke said it had been a great year despite the COVID-19 pandemic.

“Alcidion has delivered a strong final quarter to close an exceptional year of growth … despite being generated in challenging circumstances under the backdrop of COVID-19, particularly in the UK,” Ms Quirke said.

“We have been able to increase market share across all our core geographies, signing important new and renewed contracts that provide a solid foundation heading into the new financial year.”

Alcidion was trading up 7.04 per cent at 38 cents per share at 10:36 am AEST.

ALC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.